Is Rize Oncology Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Rize Oncology Inc (GTTX.CN) is currently classified as NOT HALAL as of July 2025. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Rize Oncology Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Rize Oncology Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Rize Oncology Inc?

Muslim investors may consider investing in Rize Oncology Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Rize Oncology Inc classified as NOT HALAL?

Musaffa determines the Shariah status of Rize Oncology Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Rize Oncology Inc updated?

The Shariah compliance status of Rize Oncology Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Rize Oncology Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Rize Oncology Inc?

You can check the latest Shariah compliance status of Rize Oncology Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

GTTX.CN Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: July 16, 2025

Report Source: 2025 1st Quarter Report

Rize Oncology Inc. Stock Analysis GTTX.CN

Canada N/A Nano Cap Report: Q1, 2025

Rize Oncology, Inc. is a genetic medicines company, which engages in the creation of gene editing therapies based on the GeneTether platform. The company is headquartered in Kelowna, British Columbia. The company went IPO on 2022-03-28. The firm is focused on advancing treatments for soft tissue sarcoma. The company is developing STS-201 for the treatment of soft tissue sarcoma. STS-201 is a small-molecule drug candidate that has exhibited significant utility in soft tissue sarcoma, as well as other types of cancers and certain proliferative diseases.

Key Statistics of Rize Oncology Inc (GTTX.CN)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$0.03$0.06

Today's Open

$0.06

Volume

9548.00

P/E Ratio (TTM)

52 Week Range

$0.06$0.15

Market Cap

2.27M

Avg. Volume

11.67K

Dividend Yield

Financial Metrics & Statements of Rize Oncology Inc (GTTX.CN)

FAQ's for Rize Oncology Inc (GTTX.CN)

According to Musaffa’s Shariah screening methodology, Rize Oncology Inc (GTTX.CN) is currently classified as NOT HALAL as of July 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.